This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
1
Not just “study drugs” for the rich: Stimulants as moral tools for creating
opportunities for socially disadvantaged students
ABSTRACT
A pervasive argument in the cognitive enhancement literature is that using
stimulants in populations of healthy but socially disadvantaged individuals
mistakenly attributes pathology to non-pathological individuals who experience
social inequalities. As the argument goes, using stimulants as cognitive-
enhancing drugs to solve the social problem of poorly educated students in
inadequate schools, misattributes the problem as an individual medical problem,
when it is really a collective socio-political problem. I challenge this argument on
the grounds that not all types of enhancement have to be explained in medical
terms, but rather a least one conception of enhancement can be explained in
social terms—opportunity maintenance. Therefore I propose that as a moral
requirement we ought to explore whether stimulants could be an adequate
means of remedying the social inequalities that are born from inadequate schools
based on the potential opportunities that are to be had from such use of
stimulants.
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
2
A pervasive argument in the cognitive enhancement literature is that using
stimulants in populations of healthy but socially disadvantaged individuals
mistakenly attributes pathology to non-pathological individuals who experience
social inequalities.1 As the argument goes, using stimulants as cognitive
enhancing drugs2 to solve the social problem of poorly educated students in
inadequate schools, misattributes the problem as an individual medical problem,
when it is really a collective socio-political problem. The argument concludes that
medical interventions ought to be reserved for the treatment of deficiencies in
bodily, mental, or emotional functioning and not for the enhancement of normal
bodily functioning. This argument however, places more emphasis on a narrow
conception of proper uses of stimulants rather than ways that stimulants can help
us meet moral duties to the least well off individuals in our society. In this article I
examine this narrow conception of stimulants within the context of my proposal—
as a moral requirement we ought to explore whether stimulants could be an
adequate means of remedying the social inequalities that are born from
inadequate schools based on the potential opportunities that are to be had from
such use of stimulants.
I do not challenge the argument that using stimulants medicalizes a social
problem insofar as it identifies the problem of unlearned students in inadequate
schools as a social problem and not as a medical problem. However, I do
1 Alan Schwartz presents this argument in his 2013 article “The selling of attention deficit disorder” in the New York Times. I discuss this article later. 2 In this article I refrain from using the term “cognitive enhancing drugs” and opt to use the term “stimulants” because not all drugs that can benefit disadvantaged children will enhance their cognition. Some uses of drugs, or stimulants that can benefit disadvantaged children may be an increase of motivation.
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
3
challenge the assumption that once the problem is identified, that stimulants, as
typical medical interventions, cannot be a proper solution to the problem. I
challenge this assumption on the grounds that not all types of enhancement have
to be explained in medical terms, but rather at least one conception of
enhancement can be explained in social terms.
To make my proposal clear, first I discuss common views of cognitive
enhancing drugs. Then I discuss why the treatment/enhancement distinction, a
conception of distributive justice is not an appropriate view of cognitive
enhancing drugs when they are used as potential tools to help correct social
deficits and facilitate wellbeing. In this article I propose that we consider
stimulants as a possible solution to social deficits when social institutions fail to
initiate other solutions. Theoretically, stimulants may not be the optimal solution
to the problem; the problem may be better met with a wide variety of policy
changes. However, stimulants may be a better practical and just solution in our
current unjust situation.
Since my proposed use of stimulants is not treatment, nor enhancement, I
propose a new term—opportunity maintenance. I argue that if we view stimulants
as opportunity maintenance, rather than treatment or enhancement, we are free
to from the constraints that the treatment/enhancement distinction places on
uses of stimulants. Next, I discuss objections to using stimulants as social tools.
Lastly, I discuss bigger questions that using stimulants as social tools pose but
do not have the space to address.
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
4
The broad spectrum of stimulant use
Within the past couple of decades or so bioethicists, physicians, and
popular scholars have debated the ethical use of stimulants, such as Adderall,
Ritalin, Focalin, Vyvanse, and Concerta (Schwartz 2012; Schwartz 2012b).
Although they are sometimes used to treat disorders, such as narcolepsy and
depression, they are typically used to treat Attention Deficit Disorder (ADD) and
Attention Deficit Hyperactivity Disorder (ADHD). For example, Adderall is often
prescribed to individuals with ADD or ADHD (Adderall U.S. drug label) to give
them greater control over their behavior and cognitive functions, including
improved motivation and alertness, improved abilities to retain information, and
improved ability to sift through large amounts of information and determine what
is irrelevant (Sandberg, 2011). It has been questioned whether Adderall can offer
these same benefits to individuals without ADD or ADHD (Smith et al. 2013). The
belief that Adderall can augment capabilities has led to individuals without ADD
or ADHD to be frequent users of the drug. Typically, the debate over stimulants
concerns their use by pathological and non-pathological individuals. Since
stimulant use by individuals with cognitive, behavioral, or emotional disorders is
less debatable and somewhat less controversial, in this article I focus on a more
contentious use of stimulants—use by nonpathological individuals.
Individuals without cognitive, behavioral, or emotional disorders,
individuals who are otherwise healthy, have been known to take stimulants. It
has been reported that some Silicon Valley executives (Arrington 2008) and
military pilots (Talbot 2009) have been known to take the drug Provigil for
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
5
increased alertness, a drug typically used to treat narcolepsy; however, a large
portion of the literature concerning the use of stimulants by individuals without
cognitive, behavioral, or emotional disorders are school age and college age
students. Alan Schwarz has written extensively on the use of stimulants by these
groups in the New York Times, therefore, I will rely on his depiction of the more
controversial uses of stimulants.
In a 2012 New York Times article, Schwarz gives an account of a non-
traditional approach to education reform by Dr. Michael Anderson, a physician in
the state of Georgia. Anderson intentionally, falsely diagnoses his school-age
patients with ADHD when the individual is performing poorly in school and is a
member of a low-income family. These false diagnoses allow him to prescribe
stimulants to his patients to help modify their behavior and/or cognition and
thereby facilitate their academic success in financially struggling schools. In this
instance, Adderall can be thought of as treating the adverse outcomes of social
barriers that impair his patients’ academic success.
In the following year, Schwarz (2013) wrote about Dr. Joseph Biederman,
a child psychiatrist and prominent advocate for stimulants. His studies, which are
financed by drug companies, have been used by some of those very same drug
companies to advocate for a more widespread use of stimulants, including
Adderall. Schwarz recalls a statement that Biederman made in 2006: “If a child is
brilliant but is doing just O.K. in school, that child may need treatment, which
would result in their performing brilliantly at school.” These thoughts on Adderall
sum up his beliefs (and the beliefs of many others) that stimulants can be used to
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
6
make good students, better students. Although some believe that Biederman’s
intentions are to truly help children with ADHD, they worry that drug companies
will use Biederman’s studies to create more intense and targeted advertisements
for stimulants. The other concern is that more intense and targeted
advertisements for stimulants will result in an increase in using stimulants to treat
behavior that is not symptomatic of ADHD without adequate research to support
this as an appropriate use of stimulants (Schwarz 2013).
In the same 2013 article, Schwarz writes about Dr. Keith Conners, a
psychologist and professor who is one of those concerned about the current and
potential results of Biederman’s actions. Conners laments the rising diagnoses of
ADHD in school age students and the corresponding rise in prescriptions of
stimulants. Conners is representative of a growing concern that physicians are
falsely diagnosing children and adolescents with ADHD for many reasons,
including pharmaceutical companies increasingly marketing stimulants to families
and physicians, and on some occasion, marketing them directly to children.
Schwarz (2012) and others (Brandt et al. 2014; Moore et al. 2014; Smith
et al. 2013) have also written about another aspect of the stimulant debate—the
use of stimulants as “study drugs.” The most frequent users of “study drugs” are
students in affluent families who attend prestigious and academically rigorous
schools. There is a subset of students ranging from high school students to
college students who have not been diagnosed with ADHD, but who obtain
stimulants (most commonly Adderall) from friends who have prescriptions or by
persuading physicians to give them prescriptions for stimulants by telling false
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
7
tales of anxiety and loss of concentration. Students then take the pills orally or
snort them through the nose believing them to be study aids. Some students
without ADHD claim that stimulants give them more motivation, more focus, and
increased alertness (Vrecko 2013), which is then used to perform well on
assignments in school,3 and balance academic demands, with extracurricular
activities, and domestic duties. Opponents of such use of stimulants cite the risks
of altering the developing minds of children and other potential risks to health
such as drug addiction, insomnia, and cardiovascular irregularities (Sussman et
al. 2006).
Another side of the stimulant debate is characterized by the belief that the
bigger problem is the pressure placed on students to succeed. This pressure
drives them to use stimulants to meet the expectations of their parents, teachers,
and coaches. In instances of this sort, Margaret Talbot of the New Yorker calls
stimulants “drugs that high-functioning, overcommitted people take to become
higher-functioning and more overcommitted” (Talbot 2009). Ultimately, those who
support this side of the debate argue that the problem is how we measure
success and that we need to change academic standards to reflect students’
wellbeing (Schwarz 2012). The concern is that such use of stimulants treats
students who cannot meet normative expectations, while the real problem of
enormous expectations is left untreated.
3 Some students without ADD or ADHD have also been known to use stimulants to perform well on the SATs making some question the fairness of college admissions.
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
8
I have just canvassed the major topics in the cognitive enhancement
debate. These topics in the debate focus on maximizing resources or abilities
that individuals already possess, use, and benefit from in a desirable and
adequate environment, but seek greater benefit; however, the topic that I am
concerned with in this article is less discussed within the cognitive enhancement
debate. Here, I focus on maximizing abilities that individuals may or may not
possess and use, but cannot benefit from because of their undesirable and
inadequate environment.
Many schools in America do not have the resources to properly educate
children.4 For whatever reason, be it poor educational policies or a failure of
leadership, they lack the staffing, financial resources, and equipment necessary
to give students a proper education. Schools with these problems are typically in
lower socioeconomic communities, and commonly populated by marginalized
populations of a lower socioeconomic status. One way we know that these
schools are inadequate is by comparing them to schools that, unlike them,
produce well-educated students who successfully complete exams and
standardized testing,5 complete high school, and go on to pursue higher degrees
of education. Presumably, these schools (and perhaps the families that benefit
from them) have adequate resources to accomplish their academic goals. The
problem is that because some schools (and perhaps families) do not have the
4 I acknowledge that a children’s home life can also greatly influence their academic success. 5 Though test scores are not always a proper way to measure academic success, it is at least one measurement of success that we have that can reveal disparities in education.
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
9
relevant resources, they produce improperly educated students, which puts these
students at a disadvantage when competing for social resources with students
who attend adequate schools.6
In the commonly cited A Theory of Justice, John Rawls states that the
circumstances of our birth ought not to determine the opportunities in life that are
available to us. In the case of disadvantaged children we are allowing the
circumstances of their birth to dictate the futures available to them when we do
not take on the moral obligation to remedy their academic environments. We
could say that their talent and effort ought to help them relieve themselves of
their circumstances, but their surroundings prohibit their talent and efforts from
being used to create opportunities for themselves (similar to the fallacy of the
commonplace “pull yourself up by your own bootstraps,” which is impossible to
do if you do not have any bootstraps).
What morally matters when we are disadvantaged through luck, or
through no choice of our own, is how disadvantages affect access to resources
and how we address these disadvantages. Stimulants could be one way to
address these disadvantages by giving students the tools to function within their
disadvantaged setting. Some may be unwilling to use stimulants for these
purposes for reasons that I have already addressed; however, I argue that we
have to be willing to consider stimulants as an option because we are not
6 This assumes, of course, that students in adequate schools are properly educated and can reap the benefits of their proper education. This is not to disregard those students in adequate schools who do not make good grades and those students in inadequate schools who do make good grades. The idea is that the former students start off with the resources in their favor, while the latter students do not.
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
10
correcting students’ disadvantages in other, more traditional ways. Addressing
the problem of poor schools with increased funding, better training and pay for
teachers, and updated teaching resources are all ways that could improve poor,
underperforming schools, and make stimulants not needed (or less needed) but
are all avenues that we as a society have decided that we are unwilling to
pursue. So while we are ignoring the problem, some students are being deprived
of the social and health benefits of a good education, while other students whose
schools are not plagued by these issues are not.
I have presented a sketch of multiple kinds of uses of stimulants and the
purposes of those uses that are a part of the cognitive enhancement debate. I
have also presented the use of stimulants that I am more concerned with—the
use of stimulants by disadvantaged students. The different sides of the debate,
including the side that I offer, diverge on many issues related to the use of
stimulants, showing that the use of stimulants is complicated and at times
controversial. One source of their differing conclusions about cognitive enhancing
drugs maps onto the treatment/enhancement distinction.
The problem with the treatment/enhancement distinction
The treatment/enhancement distinction is a theory of just health care in
which there is thought to be a distinct line between treatment and enhancement.
Treatment is characterized as medical interventions necessary to feign off or
cure diseases. By contrast, enhancement is characterized as medically
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
11
unnecessary interventions meant to improve upon normal functioning (Buchanan
2011; Daniels 2000, 2001).
The treatment/enhancement distinction relies on contentious explanations
of key concepts such as normal, health, and disease.7 It has even been
questioned in the literature if we can adequately discuss enhancement because
of these contentious terms (Wolpe 2002). Barring a long and in depth discussion
of each key concept, for my purposes here, it will suffice to say that the
therapy/enhancement distinction is used to separate justifiable uses of medicine
from unjustifiable uses of medicine. Per the treatment/enhancement distinction,
this is the normative conclusions that follows: it is justifiable to use stimulants for
therapeutic purposes, namely to treat mental or bodily deficiencies; any other use
of stimulants is enhancement, and therefore, unjustifiable (or at least not a
priority). For example, the idea that we ought not to diagnose students with
ADHD who have not met the proper diagnostic standards for the sake of their
academic success, relies on the idea that medical interventions are only
appropriate to treat biological deficiencies. When there are no biological
deficiencies, as for these students, enhancement practices are inappropriate.
A prominent explanation of enhancement includes enhancement as
interventions that increase human functioning beyond good health.8 Here is
7 I have discussed this elsewhere in “How empirical and social explanations of normal influence decisions to treat the neurodiverse.” 2013 In Ethics and Neurodiversity. (ed) C. Herrera and Alexandra Perry. Cambridge, UK: Cambridge Scholars Press. 8 There are a few explanations of enhancement in the current literature. Savulescu, J., A. Sandberg, and G. Kahane (2011) give a good overview of these explanations.
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
12
where the limitations of the treatment/enhancement distinction fail positions like
mine. Because the treatment/enhancement distinction is thought of in medical
terms and enhancement is thought of as the negation of therapy, it imposes
gratuitous constraints on enhancement practices, namely that meeting social
needs (when biological deficiencies do not exist) is not a part of the
enhancement agenda.
Norman Daniels (2000) gives an objection to the treatment/enhancement
distinction that captures the limitations it poses on the use of medical resources.
Daniels’ objection is that the treatment/enhancement distinction does not have
the moral strength that we impose on it.9 He argues that some times the reasons
that we are obligated to assist people with diseases and disabilities may also
obligate us to assist people with nondisease conditions. For the sake of justice,
disadvantages obligate us to assist individuals with nondiseases; and individuals
can be disadvantaged by other states of being besides poor health. But if we rely
on the treatment/enhancement distinction to guide our moral obligations only
those disadvantages created by poor health ought to be treated with medical
resources. Daniels’ objection to the treatment/enhancement distinction shows
that the treatment/enhancement distinction does not always perfectly map onto
or obligations.
Not treatment, not enhancement, but opportunity maintenance
9 Daniels also questions whether we can distinctly draw a persuasive line between therapeutic services to ameliorate disease and disability and enhancing normal traits.
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
13
I have argued that “treatment” is not an appropriate explanation of my
proposed use of stimulants—as a possible supplement for social
disadvantages— as the students that I am concerned with are not pathological. I
have also argued that “enhancement” is neither an appropriate explanation
because enhancement augments normal states and I’m arguing that
disadvantaged children are not normal in socially relevant ways. The dilemma
that my argument poses for the treatment/enhancement distinction is that I want
to explore stimulants’ ability to remedy social deficits, not biological deficits.
For my proposal we have to discard the treatment/enhancement
distinction because it ignores the problem of abnormal social health, which
includes socially disadvantaged children—a group who has a great stake in the
cognitive enhancement debate. Neither treatment nor enhancement can properly
address the ways in which they are disadvantaged and the ways in which
medical resources can potentially alleviate their disadvantages. Therefore, I
propose an alternative term—opportunity maintenance—a term that focuses on
the ways that opportunities can impact our ability to live the kind of lives that we
want to live.
Opportunities are important for many reasons. In “Bottlenecks: A new
theory of equal opportunity,” Joseph Fishkin (2014) lists why opportunities are
important and worth securing:
Opportunities open up the freedom to do and become the things we otherwise could not. […] Equal opportunity expands the range of paths open to us—educationally, professionally, and in other spheres—thereby giving us the freedom to pursue lives whose contours are to a greater degree chosen by us, rather than dictated by limited opportunities. (p. 2)
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
14
The goal of opportunity maintenance is to make undesirable environments have
less control over the futures open to disadvantaged children and to explore
ways—medical and/or social—to create new opportunities for healthy lives.
Access to education (presumably good education) is a social determinant
of health (World Health Organization 2011). Good health and education are
therefore intimately intertwined, making opportunities the product of this intimate
relationship. Education promotes good health and together they help us to
secure those opportunities that help us live the kinds of lives that we desire. As
such we have to explore all possibilities for securing education and opportunities
for the sake of health. But when access to good education is not an option (likely
because we are not taking the appropriate actions to make it an option) we have
to find other ways for students to function within their current academic
environment and reap all of the possible benefits their situations have to offer.
Relinquishing the treatment/enhancement distinction and using the idea of
opportunity maintenance allows us to further explore these possibilities by
expanding the uses of our current resources to create more opportunities.
The problems that socially disadvantaged students pose for the
treatment/enhancement distinction are avoided if we rely on opportunity
maintenance. Opportunity maintenance uses medical resources, but not for
biological deficiencies. Without assigning pathologies to children, opportunity
maintenance uses medical resources to help secure opportunities that can lead
to better health. Just as biological deficiencies can limit the kinds of people that
we can become, social deficiencies can also be limiting. Opportunity
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
15
maintenance recognizes the potentially limiting nature of social deficiencies and
medicine’s resources potential to help minimize the effects of social deficiencies.
Opportunity maintenance also acknowledges that abnormalities other than
biological abnormalities can impact opportunities, justifying opportunity
maintenance practices for individuals who are biologically normal, but who are
not socially normal. Enhancement practices, on the other hand, are for
individuals who are already functioning normally, without regard to social
normalcy. And if biological deficits obligate us to take moral action, then social
deficits ought to also obligate us to take moral action.
Opportunity maintenance allows us to explore whether students in
inadequate schools who do not have the academic and/or familial resources to
facilitate academic success could benefit from the full utility of stimulants without
having to view students as pathological. If we were to think of stimulants from the
viewpoint of opportunity maintenance, rather than treatment or enhancement, in
social terms rather than medical terms, the treatment/enhancement distinction
would matter less and the moral obligations that medical resources can help us
meet would matter more. Opportunity maintenance brings disadvantages, social
deficits, and opportunities to the forefront; it liberates us from the constraints that
the treatment/enhancement distinction places on medical practices and we are
free to do the empirical work necessary to determine if medical resources can
help compensate for inadequate social conditions that have a disparately
inhibiting effect on some groups of students’ health.
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
16
Opportunity maintenance as wellbeing
Opportunity maintenance has the same ends as treatment and
enhancement—health. At least one way to explain health is in terms of wellbeing.
Opportunity maintenance allows us to use the resources that are available to us
to discover new ways for securing wellbeing, namely ways that secure
opportunities. Our available resources then become tools to shape our lives in
the ways that we want. Next, I look at possible conceptions of wellbeing in which
there is a relationship between opportunities, resources, and wellbeing.
Prioritarianism gives an account of the relationship between wellbeing and
resources. Prioritarianism, as a matter of justice, distributes resources by
prioritizing the wellbeing of individuals that are the least well off over individuals
that are better off. Wellbeing can be defined in terms of general wellbeing,
economic wellbeing and/or access to resources (Arneson 2010).
Prioritarianism has been criticized for being a leveling down principle that
sets the unattainable goal of strict equality. Putting an analysis of the criticisms
aside, it will suffice for my purposes here to say that in response to criticisms,
some prioritarians have adopted an equality of opportunity account of justice. Its
goal is not equality of outcomes but rather assuring that individuals have an
equal opportunity to obtain desirable resources or that we have fair shares of
total resources (Anderson, 1999).
Also focusing on resources and wellbeing, in numerous articles Julian
Savulescu writes that enhancement10 practices can be tools to acquire what we
10 What Savulescu views as enhancement, I view as opportunity maintenance.
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
17
value in life. For example, Savulescu argues that we have a moral duty to use
the tools that biotechnology has afforded us to increase children’s wellbeing
(Savulescu 2005, 2006). Savulescu gives the example of the moral duty that
parents would have to prevent their child from contracting HIV if a simple
intervention were available, making failure to do so a moral wrong. If we have the
tools to treat medical conditions and we stand by and do nothing, we are acting
immorally. Similarly, if we have the tools to treat “social disabilities” and we do
not, we are acting immorally. The similarity in duty is derived from Savulescu’s
views on disease and treatment:
I don’t think there’s any moral difference between treatment of disease and enhancement. What ultimately matters to human beings is wellbeing…If that’s what really matters, then we have good reasons to treat disease. In so far as other things, like IQ or impulse control, affect our wellbeing, we have exactly the same reason to change them. (Maley 2008) Although we may have a moral duty to treat disease for the sake of health, health
is not an intrinsic good; health is an instrumental good that allows us to live a life
of wellbeing. But if wellbeing were an intrinsic good, then we would have a moral
duty to enhance our lives for the sake of wellbeing (Savulescu 2005).
Similar to prioritarianism and Savulescu’s idea that enhancement
practices are life’s tools, the goal of opportunity maintenance is that people have
equal opportunity to obtain resources so that they have an equal chance at
obtaining wellbeing. To obtain wellbeing we have to continuously make use of
the available tools that biotechnology affords us. Human ingenuity and curiosity
has allowed us to shape our environment to make it more conducive to our
wellbeing. We have transformed our small huts to lavish mansions and we have
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
18
changed simple animal skins to designer clothing. We have always used tools to
shape our lives. Using biotechnology to create opportunities for people whose
environment has not naturally given them those opportunities is just another form
of human ingenuity to create wellbeing.
Wellbeing is a normative concept, and proper education is not the only
relevant factor when developing wellbeing. However, we can argue that schools
without the ability to properly teach their students are doing a great disservice to
their students and at the least are certainly not contributing to any reasonable
idea of their wellbeing. Schools with these problems are typically in lower
socioeconomic communities, and commonly populated by students in
marginalized populations. These students are already disadvantaged in other
ways that can jeopardize their wellbeing. Exploring all possible options for
alleviating the sources of their disadvantages, and certainly exploring ways not to
surplus their disadvantages is a moral obligation based on what is at stake to be
lost—a healthy life.
Stimulants are not magic pills, however, and they alone will not increase
wellbeing. Stimulants will not update outdated textbooks, stimulants will not
decrease class sizes, nor will stimulants teach teachers new and innovative
teaching practices when old ways have failed their students. Stimulants may
contribute best to wellbeing by being just one part of social reform, with the other
parts of social reform being reformation of these negative aspects of our
educational system. However, when we aren’t taking the necessary action to
remedy these negative aspects of our educational system it is our moral
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
19
obligation to determine other routes of wellbeing. Stimulants are a route worth
exploring. We have to determine if stimulants can help students maximize the
minimal resources that they are given by improving their ability to function in their
undesirable environments. In this instance, stimulants would become tools of
morality, giving us the potential to remedy a social wrong.
Objections
In this article the main objection that I respond to is that it is improper to
use stimulants to help the disadvantaged if they have not been diagnosed with a
medical disorder. I have argued that the disadvantages that some students
experience can be detrimental to their health by limiting the opportunities
available to them, justifying at least further exploration of the social uses of
stimulants. I will now respond to other possible major objections to my argument.
It is likely that there are other objections, but I do not have the space to address
them all so I will only address the more prominent objections.
The first objection I will respond to is modeled after an example given by
Joseph Fishkin in “Bottlenecks: A new theory of equal opportunity.” Fishkin
(2014) gives the example of appearance discrimination in which opportunities are
withheld from individuals who do not meet certain standards for proper
appearances, e.g. misshapen noses or crooked teeth. In response to
appearance discrimination some individuals may prefer antidiscrimination laws,
but others may prefer the chance to change their appearance, e.g. orthodontia
and rhinoplasty, to meet the standards by which they are judged. One response
that Fishkin offers is to make health insurance cover medical treatments to
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
20
resolve undesired appearances. Fishkin looks at situations like these in terms of
opportunity pluralism. By offering a chance to fix appearances so that individuals
are not subject to appearance discrimination, we are changing the diversity of
appearances found in our societies in a way that reduces opportunity pluralism.
We are also making strong normative claims about what is beautiful and ugly.
Most societies are not made up of people who all agree on what the standards
for beautiful and ugly are, or what are normal and abnormal appearances.
Fishkin’s point is that in our attempts to help people overcome disadvantages we
could be creating more hurdles that individuals have to overcome to secure
opportunities.
Fishkin’s example of undesired appearances and their relation to
opportunities parallels a concern that my proposal may inspire: When we use
drugs to try to change the ways that young students are disadvantaged by
education systems we are removing diversity from society by making strong
claims about what is normal and making students fit this idea of normalcy. To
respond to this concern, I follow Fishkin’s approach to appearance
discrimination. His response to appearance discrimination is to that we ought to
help the people whose extreme disfiguration puts them severely outside the
standards of normalcy, while attempting to avoid practices that suggest that
everyone must fit specific norms of appearances.
When applied to my proposal, Fishkin’s response would look something
like this: Help the students whose extreme disadvantages puts them severely
outside of the normal range of the opportunities we can expect individuals to
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
21
have, while attempting to avoid prescribing specific ways of achieving wellbeing.
Using the idea of opportunity maintenance to explore new approaches to
disadvantages does not prescribe one way to be normal, but rather
acknowledges that our education system is unlikely to undergo drastic changes
any time soon. Therefore, there are certain confines in which students have to
work within to receive a good education. Helping students work within these
confines gives them the opportunity to be more autonomous and define wellbeing
for themselves as education tends to give us more control over our lives. But
they cannot have this control over their lives if they first do not have the proper
tools (i.e. education). Overall, education provides the opportunity to define
normalcy for our self.
Another possible concern that my proposal my raise surrounds the
question of privilege: Are we changing who is privileged? Are the once under-
privileged group now the privileged group, making the once privileged group now
the newly under-privileged group? I find this objection to be easily dismissed on
the groups that this is a classist argument concerned with maintaining current
power structures. At the heart of this objection is a desire to keep privileged
groups comfortable in their privileged positions and to recognize their privileges
by having an under privilege class to compare themselves to.
My proposal does not aim to take away stimulants from the privileged
class (currently the most frequent users of stimulants). Privileged groups will
likely continue to use stimulants and because many individuals in these groups
have the resources and environments to make stimulants more effective, they
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
22
will likely continue to hold their position as the privileged class. My proposal aims
to explore more ways in which we can give more people the opportunity to be
relieved of the disadvantages that their environments impose on their futures. My
proposal may create some resentment from the always-privileged group, but we
have to seriously question the validity of that resentment when privileged groups
have other resources that do not impose disadvantages on their lives in the same
ways that poor education imposes disadvantages on some individuals.
Further questions
Exploring the use of stimulants to aid social deficits raises more questions
than those I have addressed in this article. In particular, my proposal raises
questions concerning disparities in wealth and health, how these disparities
impact opportunities, and the best ways to address these disparities.
Disadvantages that contribute to deficiencies in opportunities are rarely created
by one system or institution, but tend to be created by an interaction of multiple
systems and institutions. As such, solutions that target one aspect of the chain of
health may not be as desirable as comprehensive solutions that attack the
problem in its entirety. What this solution would look like, who would be the
agents of change, and who would enforce this solution and how are all questions
that we have to ask if we favor comprehensive solutions to disparities in wealth
and health, thus disparities in opportunities.
My proposal also raises questions about what is considered normal and
what threats to our normalcy ought to matter. More importantly, once we have
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
23
established what is normal and what is outside of the range of normalcy, we then
have to determine what we are willing to do to as a society to put people within
normal ranges. Using stimulants to help free individuals of binding social
abnormalities raises the question of whether we can change what is considered
normal. Can stimulants make what was once normal, abnormal, changing the
threshold for what is considered normal? And if so, will we be forced to find new
ways to help the newly abnormal? These are all questions that we have to
consider when we search for news ways to address social abnormalities.
Conclusion
In this article I have responded to the argument that students without
biological deficits or abnormalities ought not to use stimulants because they are
normal. My response is that some students in disadvantaged environments,
namely poor, inadequate schools have morally relevant social disadvantages that
warrant an exploration of stimulants’ ability to remedy their situation. I have
argued that neither treatment nor enhancement is a proper explanation of this
proposed use of stimulants and opportunity maintenance is a better explanation
of my proposal. Opportunity maintenance focuses on the relationship between
good education and opportunities, and health in terms of wellbeing.
Changing the way that we talk about stimulants is one step in considering
the full uses of stimulants for disadvantaged students, while keeping in mind
what is at stake for this population—wellbeing. Opportunity maintenance avoids
assigning pathologies to socially deprived individuals who are not biologically
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
24
pathological. This view also avoids assuming that the problem is biological,
rather it is compatible with presuming that the problem is social, and concluding
that stimulants can effect a social solution.
For some, nonmedical uses of stimulants are morally impermissible
because of assumptions about the kind of practices used to enhance children
and assumptions about the results of these practices. We are morally concerned
about the kinds of people children who use stimulants will turn into when they
use stimulants as “study drugs.” In contrast, we don’t seem to apply these same
moral concerns to the kinds of people that disadvantaged children will turn into if
we do not explore broad uses for stimulants. And until we change how we view
nonmedical uses of stimulants, our tools to fight social justices will be limited by
our own assumptions. In our discussions of stimulants, we have to be less
concerned with abuses of stimulants and more concerned with stimulants
abilities to minimize the effects of social injustices and the ways in which
injustices limit the kinds of persons we can become.
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
25
References
Adderall U.S. Drug Label. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24af5ced-ed01-4188-95f0-b6b8e4f70aab. Anderson, E. S. 1999. What is the point of equality? Ethics, 109(2): 287-337. Arneson, R. J. 2010. Disadvantage, capability, commensurability, and policy. Philosophy, Politics, and Economics, 9: 339-357. Arrington, M. 2008. How many Silicon Valley startup executives are hopped up on Provigil. Techcrunch.com. http://techcrunch.com/2008/07/15/how-many-of-our-startup-executives-are-hopped-up-on-provigil/. Brandt, S. A., E. C. Taverna, and R. M. Hallock. 2014. A survey of nonmedical use of tranquilizers, stimulants, and pain relievers among college students: Patterns of use among users and factors related to abstinence in non-users. Drug and Alcohol Dependence, 143: 272-276. Buchanan, A. 2011. Better than Human. New York: Oxford University Press. Fishkin, J. Bottlenecks: A new theory of equal opportunity. New York: Oxford University Press. Maley, J. 2008. Changing the nature of human beings. The Sydney Morning Herald. http://www.smh.com.au/news/science/this-man-advocates-cloning-anddrugs-in-sport/2008/08/09/1218139179842.html. Moore, D. R., D. A. Burgard, R. G. Larson, and M. Ferm. 2014. Psychostimulant use among college students during periods of high and low stress: An interdisciplinary approach utilizing both self-report and unobstrusive chemical sample data. Addictive Behaviors, 39: 987-993. Rawls, J. 1999. A theory of justice (revised edition). Cambridge: Harvard Univeristy Press. Sandberg, A. 2011. Cognition enhancement. In Enhancing Human Capacities, ed. Savulescu, J. R. ter Meulen, and G. Kahane, 71-91. Malden: Blackwell Publishing. Savulescu, J. 2005. New breeds of humans: The moral obligation to enhance. Ethics, Law, and Moral Philosophy of Reproductive Biomedicine, 1(1): 36-39. Savulescu, J. 2006. Justice, fairness, enhancement. Annals of the New York Academy of Science, 1093: 321-338.
This is a pre-publicationversion. The final version will be printed in American Journal of Bioethics.
26
Savulescu, J., A. Sandberg, and G. Kahane. 2011. Well-being and enhancement. In Enhancing Human Capacities, ed. Savulescu, J. R. ter Meulen, and G. Kahane, 3-18. Malden: Blackwell Publishing. Schwarz, A. 2013. The selling of attention deficit disorder. New York Times. http://www.nytimes.com/2013/12/15/health/the-selling-of-attention-deficit-disorder.html?pagewanted=all&_r=0. Schwarz, A. 2012. Attention disorder or not, pills to help in school. New York Times. http://www.nytimes.com/2012/10/09/health/attention-disorder-or-not-children-prescribed-pills-to-help-in-school.html?pagewanted=1&_r=1&ref=us&. Schwarz, A. 2012b. Risky rise of the good-grade pill. New York Times. http://www.nytimes.com/2012/06/10/education/seeking-academic-edge-teenagers-abuse-stimulants.html?ref=alanschwarz. Smith, M. E., and M. J. Farah. 2013. Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychological Bulletin 137(5): 717-741. Sussman, S., M. A. Pentz, D. Spruijt-Metz, and T. Miller. 2006. Misuse of “study drugs:” Prevalence, consequences, and implications for policy. Substance, Abuse Treatment, Prevention, and Policy 1(15). Talbot, M. 2009. Brain gain: The underground world of “neuroenhancing” drugs. The New Yorker. http://www.newyorker.com/magazine/2009/04/27/brain-gain. Vrecko, S. 2013. Just how cognitive is “cognitive enhancement”? On the significance of emotions in university students’ experiences with study drugs. American Journal of Bioethics Neuroscience 4(1): 4-12. Wolpe, P. R. 2002. Treatment, enhancement, and the ethics of neurotherapies. Brain and Cognition, 50: 387-395. World Health Organization. 2011. World conference on social determinants of health. Rio Political Declaration on Social Determinants of Health.
Top Related